Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
Rhea-AI Summary
Eli Lilly (NYSE: LLY) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities, will join a fireside chat at 1:50 p.m. Eastern time.
A live audio webcast and a replay (available for about 90 days) will be accessible through the “Webcasts & Presentations” section of Lilly's investor website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 31 | Phase 3b data | Positive | -1.4% | Combination therapy improved durable efficacy and weight-loss outcomes at one year. |
| Aug 31 | Acquisition agreement | Positive | -1.4% | Lilly agreed to acquire Merida Biosciences for up to $2.875 billion. |
| Aug 28 | FDA approval | Positive | -0.3% | FDA expanded Mounjaro's indication to reduce cardiovascular risk in type 2 diabetes. |
| Aug 26 | Real-world study | Positive | -3.5% | Zepbound use was associated with lower non-drug healthcare costs in older adults. |
| Aug 12 | Regulatory advocacy | Neutral | +0.5% | Lilly urged platforms, payment companies, and regulators to address the retatrutide black market. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive Lilly announcements were followed by predominantly negative 24-hour price reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Refer to: | Megan MacCauley; maccauley_megan@lilly.com (Media) |
Michael Czapar; czapar_michael_c@lilly.com (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-morgan-stanley-24th-annual-global-healthcare-conference-302865226.html
SOURCE Eli Lilly and Company